[go: up one dir, main page]

PL2167523T3 - Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA - Google Patents

Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA

Info

Publication number
PL2167523T3
PL2167523T3 PL08771474T PL08771474T PL2167523T3 PL 2167523 T3 PL2167523 T3 PL 2167523T3 PL 08771474 T PL08771474 T PL 08771474T PL 08771474 T PL08771474 T PL 08771474T PL 2167523 T3 PL2167523 T3 PL 2167523T3
Authority
PL
Poland
Prior art keywords
synthesis
messenger rna
rna cap
phosphorothioate analogs
reverse
Prior art date
Application number
PL08771474T
Other languages
English (en)
Inventor
Jacek Jemielity
Ewa M Grudzien-Nogalska
Joanna Kowalska
Edward Darzynkiewicz
Robert E Rhoads
Original Assignee
Univ Louisiana State
Univ Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Univ Warszawski filed Critical Univ Louisiana State
Publication of PL2167523T3 publication Critical patent/PL2167523T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL08771474T 2007-06-19 2008-06-19 Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA PL2167523T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94484207P 2007-06-19 2007-06-19
PCT/US2008/067494 WO2008157688A2 (en) 2007-06-19 2008-06-19 Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
EP08771474.7A EP2167523B1 (en) 2007-06-19 2008-06-19 Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap

Publications (1)

Publication Number Publication Date
PL2167523T3 true PL2167523T3 (pl) 2014-12-31

Family

ID=40156965

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08771474T PL2167523T3 (pl) 2007-06-19 2008-06-19 Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA

Country Status (15)

Country Link
US (1) US8153773B2 (pl)
EP (1) EP2167523B1 (pl)
CN (3) CN107501370B (pl)
AU (1) AU2008265683B2 (pl)
CA (1) CA2692906C (pl)
CY (1) CY1115525T1 (pl)
DK (1) DK2167523T3 (pl)
EA (1) EA017740B1 (pl)
ES (1) ES2500515T3 (pl)
HK (1) HK1200461A1 (pl)
HR (1) HRP20140771T1 (pl)
PL (1) PL2167523T3 (pl)
PT (1) PT2167523E (pl)
SI (1) SI2167523T1 (pl)
WO (1) WO2008157688A2 (pl)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049665A2 (en) * 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
WO2009058911A2 (en) * 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
EP2281579A1 (en) * 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CN101671669B (zh) * 2009-08-27 2012-05-02 浙江大学 一种肝癌靶向性基因表达元件ae及其应用
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3590949T (pt) 2010-10-01 2022-08-02 Modernatx Inc Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
EP2820159B1 (en) 2012-02-29 2019-10-23 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
EP2847329A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF CYTOPLASMA AND CYTOSCELETTE PROTEINS
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
AU2014218621B2 (en) 2013-02-25 2019-11-07 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
BR112016010175A2 (pt) 2013-11-11 2017-10-03 Sangamo Biosciences Inc Repressor genético, seus usos, e composição farmacêutica
PL3492593T3 (pl) 2013-11-13 2022-04-19 Children's Medical Center Corporation Regulacja ekspresji genów, w której pośredniczą nukleazy
EP3080274B1 (en) 2013-12-09 2020-06-03 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
EP3540060A1 (en) 2013-12-30 2019-09-18 CureVac AG Methods for rna analysis
DK3102673T3 (da) 2014-02-03 2020-07-06 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
ES2879373T3 (es) 2014-03-18 2021-11-22 Sangamo Therapeutics Inc Métodos y composiciones para la regulación de la expresión de proteínas de dedo de zinc
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
CN106413760B (zh) 2014-05-08 2020-01-14 桑格摩生物科学股份有限公司 用于治疗亨廷顿病的方法和组合物
EP3142707A4 (en) 2014-05-13 2018-02-21 Sangamo Therapeutics, Inc. Methods and compositions for prevention or treatment of a disease
EP3152319A4 (en) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Methods and compositions for nuclease design
AU2015273933B2 (en) 2014-06-10 2021-02-11 CureVac Manufacturing GmbH Methods and means for enhancing RNA production
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
EP4019635A1 (en) 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
CA2981077A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
MX2017013321A (es) 2015-04-22 2018-07-06 Curevac Ag Composicion que contiene arn para tratamiento de enfermedades tumorales.
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
EP3294888A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
SG10202112057QA (en) 2015-05-12 2021-12-30 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
DE202016009003U1 (de) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration
CA2986262A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2017001058A1 (en) 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
EP3906789B1 (en) 2015-09-21 2023-11-22 TriLink BioTechnologies, LLC Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas
MX2018003491A (es) 2015-09-23 2018-09-06 Sangamo Therapeutics Inc Represores de htt y usos de estos.
EP3362461B1 (en) 2015-10-16 2022-03-16 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
EP3365447A1 (en) 2015-10-21 2018-08-29 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hepatitis b virus
EP3368670A1 (en) 2015-10-30 2018-09-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
JP6976249B2 (ja) 2015-11-23 2021-12-08 サンガモ セラピューティクス， インコーポレイテッド 免疫を工学操作するための方法および組成物
EA201891212A1 (ru) 2015-12-18 2019-01-31 Сангамо Терапьютикс, Инк. Адресная дезорганизация клеточного рецептора гкгс
EP3389677B1 (en) 2015-12-18 2024-06-26 Sangamo Therapeutics, Inc. Targeted disruption of the t cell receptor
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
PL415967A1 (pl) * 2016-01-29 2017-07-31 Univ Warszawski 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
KR102378404B1 (ko) 2016-04-22 2022-03-24 비온테크 에스이 단일가닥 rna 제공 방법
EP3452493B1 (en) 2016-05-04 2025-01-15 CureVac SE Nucleic acid molecules and uses thereof
US20210162037A1 (en) 2016-05-04 2021-06-03 Curevac Ag Influenza mrna vaccines
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
AU2017261380A1 (en) 2016-05-06 2018-11-22 Editas Medicine, Inc. Genetically engineered cells and methods of making the same
JP7033583B2 (ja) 2016-07-13 2022-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド ゲノム編集効率を高めるための方法、組成物及びキット
JP2019526556A (ja) 2016-08-19 2019-09-19 キュアバック アーゲー 癌治療用ｒｎａ
PL3504229T3 (pl) 2016-08-24 2022-04-19 Sangamo Therapeutics, Inc. Regulacja ekspresji genów przy użyciu nukleaz poddanych inżynierii
KR20220145913A (ko) 2016-08-24 2022-10-31 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
CN110022904B (zh) 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
SG11201903460QA (en) 2016-10-26 2019-05-30 Curevac Ag Lipid nanoparticle mrna vaccines
EP3532106A4 (en) 2016-10-31 2020-06-24 Sangamo Therapeutics, Inc. GENE CORRECTION OF SCID-RELATED GENES IN HEMATOPOIETIC AND PROGENITANT STEM CELLS
WO2018102665A1 (en) 2016-12-01 2018-06-07 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
AU2018261366A1 (en) 2017-05-03 2019-10-31 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CTFR) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
WO2019008001A1 (en) 2017-07-04 2019-01-10 Curevac Ag NEW NUCLEIC ACID MOLECULES
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
JP7416686B2 (ja) 2017-09-13 2024-01-17 バイオエヌテック エスエー 体細胞を再プログラムするためのｒｎａレプリコン
EP3681901B1 (en) 2017-09-13 2024-03-27 BioNTech SE Method of enhancing rna expression in a cell
JP7389741B2 (ja) 2017-09-13 2023-11-30 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー Ｔ細胞受容体または人工ｔ細胞受容体を発現するためのｒｎａレプリコン
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
CN111565730B (zh) 2017-11-09 2024-09-17 桑格摩生物治疗股份有限公司 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
SG11202005760PA (en) 2017-12-21 2020-07-29 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EA202091708A1 (ru) 2018-01-17 2020-11-10 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
KR20200109358A (ko) 2018-01-17 2020-09-22 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
AU2019209292B2 (en) 2018-01-17 2023-10-05 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
MX2020010871A (es) * 2018-03-15 2020-11-09 BioNTech SE Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
DE202019006108U1 (de) 2018-04-17 2024-12-16 CureVac SE Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
JP2022500052A (ja) 2018-09-18 2022-01-04 サンガモ セラピューティクス， インコーポレイテッド プログラム細胞死１（ｐｄ１）特異的ヌクレアーゼ
US20220073962A1 (en) 2018-12-21 2022-03-10 Curevac Ag Methods for rna analysis
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
IL284535B2 (en) 2019-01-11 2025-03-01 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active ingredients
CN113710702A (zh) 2019-01-14 2021-11-26 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
EP4491229A2 (en) 2019-02-08 2025-01-15 CureVac SE Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
TWI862584B (zh) 2019-04-23 2024-11-21 美商聖加莫治療股份有限公司 染色體9開放讀框72基因表現之調節子及其用途
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
CN114502204A (zh) 2019-08-14 2022-05-13 库尔维科公司 具有降低的免疫刺激性质的rna组合和组合物
US20230090515A1 (en) 2019-12-20 2023-03-23 Curevac Ag Lipid nanoparticles for delivery of nucleic acids
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
EP4147717A1 (en) 2020-02-04 2023-03-15 CureVac SE Coronavirus vaccine
AU2021261471B2 (en) 2020-04-22 2024-10-24 BioNTech SE Coronavirus vaccine
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
AU2021286169A1 (en) 2020-06-04 2023-01-19 BioNTech SE RNA replicon for versatile and efficient gene expression
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
CN113106134A (zh) * 2020-08-20 2021-07-13 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
EP4501951A2 (en) 2020-08-25 2025-02-05 Kite Pharma, Inc. T cells with improved functionality
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
AU2021341829A1 (en) 2020-09-08 2023-04-06 BioNTech SE Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners
AU2021395736A1 (en) 2020-12-09 2023-07-27 BioNTech SE Rna manufacturing
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
AU2021405281A1 (en) 2020-12-22 2023-07-06 Glaxosmithkline Biologicals Sa Rna vaccine against sars-cov-2 variants
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
US20240229075A1 (en) 2021-05-03 2024-07-11 CureVac SE Improved nucleic acid sequence for cell type specific expression
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
AU2022317263A1 (en) 2021-07-29 2024-01-04 BioNTech SE Compositions and methods for treatment of melanoma
EP4377331A2 (en) 2021-07-30 2024-06-05 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
EP4395748A1 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CN113957108B (zh) * 2021-09-09 2025-01-10 上海兆维科技发展有限公司 一种加帽rna的合成方法以及加帽rna转录反应液
JP2024539087A (ja) 2021-10-18 2024-10-28 バイオエヌテック エスエー 修飾複製可能ｒｎａおよび関連組成物ならびにそれらの使用
AU2022372325A1 (en) 2021-10-18 2024-05-02 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
WO2023138786A1 (en) 2022-01-21 2023-07-27 BioNTech SE Analysis of rna molecules using catalytic nucleic acids
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
JP2025507751A (ja) 2022-03-01 2025-03-21 クリスパー・セラピューティクス・アクチェンゲゼルシャフト アンジオポエチン様３（ａｎｇｐｔｌ３）関連状態を処置するための方法および組成物
CN119053705A (zh) 2022-03-21 2024-11-29 克里斯珀医疗股份公司 用于治疗脂蛋白相关疾病的方法和组合物
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN114941018B (zh) * 2022-06-28 2023-09-22 翌圣生物科技(上海)股份有限公司 cap1帽类似物的合成方法
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
AU2023342641A1 (en) 2022-09-15 2025-03-27 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024193827A1 (en) 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
WO2024216217A1 (en) 2023-04-14 2024-10-17 BioNTech SE Hiv vaccine
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof
WO2025004001A1 (en) 2023-06-30 2025-01-02 Takeda Pharmaceutical Company Limited Htt repressors and uses thereof
US20250027087A1 (en) 2023-07-21 2025-01-23 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
CN119241624A (zh) * 2024-12-06 2025-01-03 上海科泽永欣生物科技有限公司 一种含hna结构的起始加帽寡核苷酸引物及其制备方法和应用
CN119306779A (zh) * 2024-12-13 2025-01-14 上海科泽永欣生物科技有限公司 一种含r构型的起始加帽寡核苷酸引物及其合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4854610A (en) * 1988-02-10 1989-08-08 Bertek, Inc. Method of making laminated articles and articles made therefrom
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US5653472A (en) * 1995-07-25 1997-08-05 The Standard Register Company Form having detachable wristband and labels
EP2251347A3 (en) * 1997-04-22 2011-02-23 Life Technologies Corporation Methods for the production of ASLV reverse transcriptases composed of multiple subunits
US6510634B1 (en) * 1997-10-14 2003-01-28 Laser Band, Llc Multiple computer generated multi-web moisture proof identification bracelets on a single form with window
US7047682B2 (en) * 2002-09-27 2006-05-23 Laser Band, Llc Wristband/label assembly business form and method
US7386949B2 (en) * 1997-10-14 2008-06-17 Laser Band, Llc Special precautions self-laminating wristband business form and method
US7017293B2 (en) * 2002-09-27 2006-03-28 Laser Band, Llc Wristband/cinch with label assembly business form and method
US7017294B2 (en) * 2002-09-27 2006-03-28 Laser Band, Llc Wristband/cinch with inboard label assembly business form and method
US6000160A (en) * 1997-10-14 1999-12-14 Riley; James M. Computer generated moisture proof identification bracelet
US6016618A (en) * 1997-11-17 2000-01-25 Avery Dennison Corporation Laminated article
AU1087301A (en) * 1999-10-15 2001-04-30 Yale University Conjoined polynucleotide catalysts
US20040261644A1 (en) * 2001-09-14 2004-12-30 Stewart Thomas R. Medical patient labeling system and method
US6788687B2 (en) * 2001-10-30 2004-09-07 Qualcomm Incorporated Method and apparatus for scheduling packet data transmissions in a wireless communication system
US6836215B1 (en) * 2002-01-22 2004-12-28 The Standard Register Company Printable identification band with top strip for RFID chip attachment
US7316358B2 (en) * 2002-03-18 2008-01-08 Precision Dynamics Corporation Identification band with adhesively attached coupling elements
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US6971200B2 (en) * 2002-09-13 2005-12-06 Chicago Tag & Label Form having a removable wristband and labels
US7000951B2 (en) * 2002-09-13 2006-02-21 Chicago Tag And Label, Inc. Form having a removable wristband and labels
US7520077B2 (en) * 2004-06-17 2009-04-21 Laser Band, Llc Cushioned wristband with self-laminating identity tag
US20050181165A1 (en) * 2002-11-13 2005-08-18 Franko Joseph D.Sr. Glue-applied resealable expanded content label
US7322613B2 (en) * 2002-12-17 2008-01-29 Precision Dynamic, Corporation Multi-part form having detachable wristband, labels and cards or the like
US7222748B2 (en) * 2003-09-26 2007-05-29 Royal Vendors, Inc. Clear door vending machine
US20050091896A1 (en) * 2003-10-30 2005-05-05 Kotik Mark M. Identification band with detachable machine-readable lables
US7320194B2 (en) * 2004-06-01 2008-01-22 Precision Dynamics Corporation Adhesive wristband without removable release liner
US7658026B2 (en) * 2006-10-27 2010-02-09 Laser Band, Llc Wristband with snap closure and patent id label
US20050285385A1 (en) * 2004-06-28 2005-12-29 Bova Antonio V Emergency medical analysis form with detachable patient identification piece and method of using same
US7417541B2 (en) * 2004-10-08 2008-08-26 Bartronics America, Inc. Identification band with regions having electro-magnetically detectable regions
US20060113788A1 (en) * 2004-11-30 2006-06-01 Laser Band, Llc. Laser printable business form having a self laminating wristband and a self laminating strip label
US7810267B2 (en) * 2005-04-21 2010-10-12 Avery Dennison Corporation Patient identification products
US20070120358A1 (en) * 2005-11-30 2007-05-31 Waggoner Bryce C Patient wristband form
US20070283607A1 (en) * 2006-06-13 2007-12-13 Printmark Industries, Inc. Printed identification band and method of manufacturing same
US20080067802A1 (en) * 2006-08-24 2008-03-20 Tri-State Hospital Supply Corporation Self-laminating label for a wristband
US8424115B2 (en) * 2006-10-27 2013-04-23 Laser Band, Llc Wristband with contoured comfort sides
EP2152160B1 (en) * 2007-06-14 2013-05-01 Precision Dynamics Corporation A closure mechanism for an identification medium adapted for receiving indicia forming material and dual closure means

Also Published As

Publication number Publication date
CY1115525T1 (el) 2017-01-04
CN104072561A (zh) 2014-10-01
CA2692906A1 (en) 2008-12-24
PT2167523E (pt) 2014-09-22
ES2500515T3 (es) 2014-09-30
US20100233757A1 (en) 2010-09-16
CN107501370A (zh) 2017-12-22
US8153773B2 (en) 2012-04-10
WO2008157688A3 (en) 2009-02-26
CN107501370B (zh) 2021-06-18
EP2167523B1 (en) 2014-07-23
CN101855231B (zh) 2014-06-11
CN101855231A (zh) 2010-10-06
CA2692906C (en) 2016-01-19
EA017740B1 (ru) 2013-02-28
DK2167523T3 (da) 2014-09-08
HK1200461A1 (en) 2015-08-07
AU2008265683A1 (en) 2008-12-24
SI2167523T1 (sl) 2014-09-30
HRP20140771T1 (hr) 2014-11-07
EA201070030A1 (ru) 2010-06-30
WO2008157688A2 (en) 2008-12-24
EP2167523A4 (en) 2011-06-15
EP2167523A2 (en) 2010-03-31
CN104072561B (zh) 2017-12-22
AU2008265683B2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
HK1200461A1 (en) Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap rna -
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
HK1125961A1 (en) Preparation containing organosilicium compound and its use
ZA201107336B (en) Synthesis of 2'-o-fucosyllactose
GB0711675D0 (en) Labelling of RNA
ZA201003941B (en) Use of rr/sr-ractopamine
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
GB0617725D0 (en) Distribution of data to multiple recipients
HK1161122A1 (en) Use of 24-norudca 24-norudca
ZA200902300B (en) Use of modified cyclosporins
ZA201001817B (en) Crystalline hydrate of betamimetika and use as medicament thereof
GB0914782D0 (en) Perfluoroparacyclophane and methods of synthesis and use thereof
GB0722759D0 (en) Antisense oligonucleotides for the modulation of gene expression and methods relating to the use thereof
GB0710869D0 (en) Distribution of data to multiple recipients
GB0822289D0 (en) "BABOO"babyseat carry
EP2063850A4 (en) VIPR1 AS MODIFIERS OF THE E2F / RB PATHWAY AND METHODS OF USE
TWM300387U (en) Improved structure of cupulate holder
TWM292311U (en) Improved structure of cosmetics container
ZA200810632B (en) Derivativs and analogs of N-ethylquinolones and N-ethylazaquinolones
GB0707985D0 (en) Easy's
GB0804248D0 (en) Fabia's messege fragrance
TWM300202U (en) Improved structure of bottle
PL379090A1 (pl) Wykorzystanie wodoru
TWM311768U (en) Improved structure of A-ladder
HU0600620D0 (en) New medical use of localanesthetics